Posts Tagged ‘patients’

Platelet Rich Plasma (PRP) Treatment in Hyderabad India

Platelet Rich Plasma Injections | Posted by admin
Sep 02 2015

What isPlatelet Rich Plasma

Eternesse Anti Aging Clinicis the only clinic in India that currently offersPRPto its patients.Platelet Rich Plasma, orPRP, isblood plasma with concentrated plateletsand othergrowth factors. The concentrated platelets found inPRPcontain huge reservoirs ofbioactive proteins, includinggrowth factorsand signaling proteins that are vital to initiate and acceleratetissue repairandregeneration. These growth factors number at least a dozen different factors. Thesebioactive proteinsinitiate connective tissue healing in tissues such asmeniscus (knee)androtator cuff tissue, boneandarticular cartilage regenerationand repair, promote development of new blood vessels, and stimulate thewound healing process.

ThePRPsignals the body to send instem cellsto repair the area of injury.PRP injectionsare sometimes done under fluoroscopic guidance (living x-ray) atEternesse Anti Aging Clinic. This is done for precise localized delivery of these healing factors into injured ligaments, muscles, and joints.

Steps Involved in Platelet Rich Plasma Therapy

Platelet Rich Plasma therapyis a treatment option for variousorthopaedic injuriesand conditions, which have traditionally required surgery or other extensive treatments.PRP injectionsare being utilized inorthopaedicswith increasing frequency and effectiveness. Injuries currently being treated with thePRP therapyare arthritis of the hip, knee, shoulder, ankle and other joints.PRPalso is utilized for soft tissue injuries such astendonitis, muscle sprainsandtears,and various types ofligament injuries. These include common tendon injuries such astennis and golfers elbow,Achilles tendonitisandknee tendonitis. PRP is also used to treat various injuries and conditions affecting (joint) injuries. These include rotator cuff and meniscus injuries.

AlthoughPRPtechnology is consideredcutting edge technology, it was initially developed 20 years ago for heart surgery to aid with the wound healing and blood loss. Its benefits are now being applied towards the facilitating of healing muscle, tendons, ligaments, articular and meniscal injuries. In fact, PRP has been widely used in Europe for many years.

To preparePRP, a small amount of blood is taken from the patients arm. The blood is then placed in acentrifuge. The centrifuge spins and separates the platelets form the rest of the blood components. The entire process takes less than 15 minutes and increases the concentration of platelets and growth factors up to 600%. Using the patients own blood, specially prepared platelets are taken and re-injected into the affected area. These platelets release special growth factors that lead to tissue healing. By using theconcentrated platelets, we increase the growth factors up to eight times which promotes temporary relief and stops inflammation.PRP injectionsactually heal the area over a period of time. This can be anywhere from one to three months.

The human body has a remarkable ability to heal itself, and by re-injecting concentrated platelets, we are facilitating thenatural healing process. ThePRPinjections are calling instem cellsto repair the area. When performing these injections, we must do whatever we can to maximize stem cell release to optimize healing.

PRP is a non-surgical technique which would suggest it is more convenient than a surgery.

Platelets are one of the primary constituents of blood along with white blood cells, red blood cells and plasma.

Platelets in the blood are responsible for the release of growth factors-power proteins which help repair and regenerate soft tissues.

Using a special procedure, we can extract the platelets out of the blood and increase their concentration by 1000 %. When injected into the knee, these highly concentrated platelets aid in the speedy healing of the knee.

We know certain factors diminish stem cell release such as smoking and alcohol intake. Obviously avoiding these pitfalls will do nothing but increase the success of the procedure. The platelets work by causing an inflammatory reaction. If we somehow diminish this inflammatory reaction than we may significantly decrease the chances of having a good result. For this reason, the use of anti-inflammatory drugs such as Advil, Aleve, Motrin, ibuprophen etc. are not recommended. This restriction should be in place for about 4-6 weeks.

The use ofomega 3-fish oiland othernatural anti-inflammatory agentsdo not seem to work the same way as theNSAIDS(non-steroidal anti-inflammatories) and are thus not restricted.

What is the number of injections that are administered?

The number of injections performed depends upon the severity and the type of condition being treated. Age also seems to have an effect on the number of injections given. Typically, younger people generally need fewer injections for the same condition than a person who is older.

Is there any pain involved?

After the injection is given, there is usually a marked increase in pain for anywhere from 5-10 days. Tylenol and possibly a mild narcotic usually handle this pain. The pain may start up again only later to go away. A good analogy is that of a roller coaster where the initial few days are like the big drop on the roller coaster than the remaining few days are like smaller dips on a roller coaster!

We are Indias bestPRP Therapy provider. Dr. Leroy Rebello is Indias foremost expert and authority on Platelet Rich Plasma. If you are anorthopedist making aninquiry for your patient or someone suffering from bone injuries please contact us. If you simply want to rejuvenate your face and body using growth cells, then you are in good hands with the countrys best PRP specialist who will attend upon you. You can call us on the number below for an initial consultation with Dr. Rebello.

Continued here:
Platelet Rich Plasma (PRP) Treatment in Hyderabad India

Platelet-Rich Plasma (PRP) Injections - HSS.edu - HSS

Platelet Rich Plasma Injections | Posted by admin
Jul 12 2015

see also Injections

Platelet activation plays a key role in the process of wound and soft tissue healing. The use of platelet rich plasma (PRP), a portion of the patients own blood having a platelet concentration above baseline, to promote healing of injured tendons, ligaments, muscles, and joints, can be applied to various musculoskeletal problems.

Ultrasound and photograph of a PRP injection into a patient’s tendon tear.

It was used as early as the 1990s in maxillo-facial and plastic surgery. PRP injections are prepared from one to a few tubes of the patients own blood with strict aseptic technique. After being centrifuged, the activated platelets are injected into the abnormal tissue, releasing growth factors that recruit and increase the proliferation of reparative cells. Ultrasound imaging may or may not be used to guide the injection.

Several clinical studies have demonstrated that PRP injections have improved function and decreased pain to various maladies, including – but not limited to – elbow, wrist, shoulder, hip, knee, and ankle tendonosis. Early work is also showing promise for osteoarthritis.

The side effects of PRP injections are very limited as the patient is utilizing their own blood, which they should have no reaction to. Some relative rest is needed immediately following the procedure, then usually followed by a progressive stretching and strengthening program.

Read this article:
Platelet-Rich Plasma (PRP) Injections – HSS.edu – HSS

Autism - Wu Medical Center - A Leading Medical Center for …

Stem Cell Medical Center | Posted by admin
Jun 11 2015

Stem Cell Therapy for AutismMay 25th, 2015

Like Wu, Xiaojuan Wang, Freda Peng, Bo Cheng, Susan Chu

Wu Medical Center

The patient is 8-year-old boy. He was presented with language, mental, behavioral and human communication disorders for the past 5 years. He was diagnosed as Autism. He was born full-term with normal delivery. He was hyperactive, upset, agitated, impaired language development and was unable to communicate with others when he was 2 years old.

Physical examination: he was stable, Skin and mucous membrane were with no yellow stain or petechia. His heart and lung were normal. He was alert, his comprehension, judgment, attention and adaptability were bad. He was hyperactive, upset, unquiet, soliloquize and he couldnt answer questions. He could count from 1-10. He couldnt cooperate with the memory, calculation ability, or orientation examinations. He seldom had eye contact with others. He couldnt cooperate with the cranial nerves, sensation and coordinated movement during examinations. The muscle power of four limbs was at level 5, his muscle tension was normal. The tendon reflex decreased. The pathological sign was negative. All of the laboratory examination and accessory examinations were normal. He was diagnosed as Autism.

Treatment target: increase the number of normal neural stem cells (NSCs) in the brain, switch on neural development, repair and regenerate the nerves. Increase the brain function, improve the patients cognitive function and communication skills.

Treatment procedure and results: We gave the patient 4 times neural stem cells (NSCs) and 4 times mesenchymal stem cells (MSCs) implantation treatment. The stem cells were activated in the patients body to repair the damaged nerves. Together with nourishment of the neurons, improve circulation, regulating the immune, daily rehabilitation training was incorporated. After the treatment, the patient was stable, developed a good spirit and mood. He seldom gets upset and he developed more concentration. He could see movies or listen to music by himself, and the duration was increased to between 30-40 minutes than before. He speaks more with family members. He could answer questions and gained more vocabulary. He could say a sentence which is made up of 6 words. His learning skill was better. The memory, calculation ability, orientation, comprehension and attention were better. He had more eye contact with others. His nerves, sensation, coordinated movement examinations and meningeal irritation sign examination cooperation degree was better.

Case analysis: Autism is also called autistic disorder, it is one subtype of the catholicity eccyliosis. Male patients were more than female as observed. This disease onset at early infancy. The cardinal symptoms: various degrees of speech disturbance, human communication disorders, less interesting or mechanic behavior. Around 3/4 young patients accompanied with visible mental retardation. The main pathogen was unclear, it may be: heredity, perinatal period factors, abnormal immune system or imbalance of various neuroendocrine and neurotransmitter function. The patient had this disease from very young, the pathogen was unclear, and his symptoms were: abnormal mind and behaviors, cognitive disorder, bad communication skills and excitement.

There are a lot of methods to treat autism, but most of them lack medical evidences and there is no best treatment plan. Our center uses advanced NSCs transplantation technique to treats patients with autism. The NSCs is used together with MSCs to make the imbedded NSCs increase the number of brain and spinal cord nerve cells, promotes nerve differentiation and growth to improve his cognition and mental. This technique was used in this patient and he recovered well and not only his cognition and mental, his self-care ability and social skills were improved also. This provided relief of mental stress and daily burden to his relatives. This brings hope to patients with this disease.

Research under our direction, the treatment result was satisfactory. During retrospective experiment on animals, we found the same program had made great advances in nerve precursor cells structure, migration, cortical tissue, neuron differentiation and connection. For example: a small group of neurons migration lag in specific area or appear in ectopia area of the patient, could result in mental hypoevolutism, epilepsy or speech impediment. This can be fixed with implantation of nerve precursor cell. The shape and structure of cortex can be normal. The safety of this treatment was confirmed in many medical literatures. But each patient need complicated clinical technology supporting, because the brain was controlled by gene in the development process, for example: when we use the NSCs to correct neuron developmental deviation and abnormality, neuron development need growth factors participation. It also need immunological surveillance. Over growth nerve will be controlled by immune system, only in that way can we get good result. All the processes need to be controlled by experienced clinician and complicated clinical technology.

Follow this link:
Autism – Wu Medical Center – A Leading Medical Center for …

Autologous Adipose Tissue Derived Stromal Vascular Fraction Cells Application In Patients - Video

Stem Cell Clinic | Posted by admin
Apr 30 2015



Autologous Adipose Tissue Derived Stromal Vascular Fraction Cells Application In Patients
The U.S. Stem Cell Clinic is founded on the principle belief that the quality of life for our patients can be improved through stem cell therapy. We are dedicated to providing safe and effective…

By: U.S. Stem Cell Clinic

Original post:
Autologous Adipose Tissue Derived Stromal Vascular Fraction Cells Application In Patients – Video

U.S. Stem Cell Clinic: Stem Cell Banking - Video

Stem Cell Treatment | Posted by admin
Apr 11 2015



U.S. Stem Cell Clinic: Stem Cell Banking
The U.S. Stem Cell Clinic is founded on the principle belief that the quality of life for our patients can be improved through stem cell therapy. We are dedicated to providing safe and effective…

By: U.S. Stem Cell Clinic

Go here to read the rest:
U.S. Stem Cell Clinic: Stem Cell Banking – Video

New Drug May Help Keep Hodgkin Lymphoma at Bay

Stem Cell Medical Center | Posted by admin
Mar 20 2015

WEDNESDAY, March 18, 2015 (HealthDay News) — An FDA-approved drug doubled the amount of time that patients with Hodgkins lymphoma survived without any progression in their disease, a new study shows.

All of the patients also received stem cell therapy along with the drug, called brentuximab vedotin.

While the results are encouraging, doctors may never know if the drug is actually lengthening patients’ lives, said Dr. Owen O’Connor, director of the Center for Lymphoid Malignancies at Columbia University Medical Center in New York City.

That’s because brentuximab is fast becoming standard care for all patients with Hodgkin lymphoma who’ve relapsed after stem cell transplant, he said. So, a trial comparing the survival of patients who got the drug against those who did not might never be feasible, due to ethical concerns.

O’Connor was not involved in the trial, which was led by Dr. Craig Moskowitz, professor of medicine at Memorial Sloan Kettering Cancer Center in New York City. His team published the findings March 18 in The Lancet. The study was funded by Seattle Genetics Inc. and drug maker Takeda.

According to the American Cancer Society, about 9,000 new cases of Hodgkin lymphoma are diagnosed each year, and more than 1,100 people die from the illness annually. The cancer most often strikes young adults.

The phase 3 trial of brentuximab vedotin included 329 patients, aged 18 and older, who were at high risk of cancer relapse or progression after undergoing stem cell transplant, in which healthy stem cells from the patient are used to replace those lost to cancer or chemotherapy.

The patients were randomly assigned to receive 16 cycles of brentuximab vedotin infusions once every three weeks, or an inactive placebo.

After two years, there was no cancer progression in 65 percent of the patients who received the drug, compared with 45 percent of those in the placebo group, the researchers found. Progression-free survival was 43 months for those who received the drug, compared with 24 months for those in the placebo group.

“Nearly all of these patients who are progression-free at two years are likely to be cured since relapse two years after a transplant is unlikely,” Moskowitz said in a journal news release. “No medication available today has had such dramatic results in patients with hard-to-treat Hodgkin lymphoma,” he said.

Read more:
New Drug May Help Keep Hodgkin Lymphoma at Bay

The Miami Stem Cell Treatment Center Announces Adult Stem Cell Public Seminars in Orlando, Florida

Stem Cell Treatment | Posted by admin
Mar 12 2015

Orlando, Florida (PRWEB) March 12, 2015

The Miami Stem Cell Treatment Center announces a series of free public seminars on the use of adult stem cells for various degenerative and inflammatory conditions. They will be provided by Dr. Thomas A. Gionis, Surgeon-in-Chief and Dr. Nia Smyrniotis, Medical Director and Surgeon.

The seminars will be held on Tuesday, March 17, 2015, at 12:30 pm, 2:30 pm and 4:30 pm at Seasons 52, 7700 Sand Lake Road, Orlando, FL 32819. Please RSVP at (561) 331-2999.

The Miami Stem Cell Treatment Center (Miami; Boca Raton; Orlando; The Villages, FL), along with sister affiliates, the Irvine Stem Cell Treatment Center (Irvine; Westlake Villages, CA) and the Manhattan Regenerative Medicine Medical Group (Manhattan, NY), abide by approved investigational protocols using adult adipose derived stem cells (ADSCs) which can be deployed to improve patients quality of life for a number of chronic, degenerative and inflammatory conditions and diseases. ADSCs are taken from the patients own adipose (fat) tissue (found within a cellular mixture called stromal vascular fraction (SVF)). ADSCs are exceptionally abundant in adipose tissue. The adipose tissue is obtained from the patient during a 15 minute mini-liposuction performed under local anesthesia in the doctors office. SVF is a protein-rich solution containing mononuclear cell lines (predominantly adult autologous mesenchymal stem cells), macrophage cells, endothelial cells, red blood cells, and important Growth Factors that facilitate the stem cell process and promote their activity.

ADSCs are the body’s natural healing cells – they are recruited by chemical signals emitted by damaged tissues to repair and regenerate the bodys injured cells. The Miami Stem Cell Treatment Center only uses Adult Autologous Stem Cells from a persons own fat No embryonic stem cells are used; and No bone marrow stem cells are used. Current areas of study include: Emphysema, COPD, Asthma, Heart Failure, Heart Attack, Parkinsons Disease, Stroke, Traumatic Brain Injury, Lou Gehrigs Disease, Multiple Sclerosis, Lupus, Rheumatoid Arthritis, Crohns Disease, Muscular Dystrophy, Inflammatory Myopathies, and degenerative orthopedic joint conditions (Knee, Shoulder, Hip, Spine). For more information, or if someone thinks they may be a candidate for one of the adult stem cell protocols offered by the Miami Stem Cell Treatment Center, they may contact Dr. Gionis or Dr. Smyrniotis directly at (561) 331-2999, or see a complete list of the Centers study areas at: http://www.MiamiStemCellsUSA.com.

About the Miami Stem Cell Treatment Center: The Miami Stem Cell Treatment Center, along with sister affiliates, the Irvine Stem Cell Treatment Center and the Manhattan Regenerative Medicine Medical Group, is an affiliate of the California Stem Cell Treatment Center / Cell Surgical Network (CSN); we are located in Boca Raton, Orlando, Miami and The Villages, Florida. We provide care for people suffering from diseases that may be alleviated by access to adult stem cell based regenerative treatment. We utilize a fat transfer surgical technology to isolate and implant the patients own stem cells from a small quantity of fat harvested by a mini-liposuction on the same day. The investigational protocols utilized by the Miami Stem Cell Treatment Center have been reviewed and approved by an IRB (Institutional Review Board) which is registered with the U.S. Department of Health, Office of Human Research Protection (OHRP); and our studies are registered with Clinicaltrials.gov, a service of the U.S. National Institutes of Health (NIH). For more information, visit our websites: http://www.MiamiStemCellsUSA.com, http://www.IrvineStemCellsUSA.com , or http://www.NYStemCellsUSA.com.

Go here to read the rest:
The Miami Stem Cell Treatment Center Announces Adult Stem Cell Public Seminars in Orlando, Florida

'Miracle' stem cell therapy reverses multiple sclerosis

Stem Cell Treatment | Posted by admin
Mar 01 2015

In the new treatment, specialists use a high dose of chemotherapy to knock out the immune system before rebuilding it with stem cells taken from the patients own blood.

Stem cells are so effective because they can become any cell in the body based on their environment.

“Since we started treating patients three years ago, some of the results we have seen have been miraculous,” Professor Basil Sharrack, a consultant neurologist at Sheffield Teaching Hospitals NHS Foundation Trust, told The Sunday Times.

“This is not a word I would use lightly, but we have seen profound neurological improvements.”

During the treatment, the patient’s stem cells are harvested and stored. Then doctors use aggressive drugs which are usually given to cancer patients to completely destroy the immune system.

The harvested stem cells are then infused back into the body where they start to grow new red and white blood cells within just two weeks.

Within a month the immune system is back up and running fully and that is when patients begin to notice that they are recovering.

Holly Drewry, 25, of Sheffield, was wheelchair bound after the birth of her daughter Isla, now two.

But she claims the new treatment has transformed her life.

It worked wonders, she said. I remember being in the hospital… after three weeks, I called my mum and said: ‘I can stand’. We were all crying.

See the original post:
'Miracle' stem cell therapy reverses multiple sclerosis

The Irvine Stem Cell Treatment Center Announces Adult Stem Cell Public Seminars in Riverside, Ontario, and Brea …

Stem Cell Treatment | Posted by admin
Feb 27 2015

Riverside, ON and Brea CA (PRWEB) February 26, 2015

The Irvine Stem Cell Treatment Center announces a series of free public seminars on the use of adult stem cells for various degenerative and inflammatory conditions. They will be provided by Dr. Thomas A. Gionis, Surgeon-in-Chief.

The seminars will be held on Saturday, March 7, 2015, at 11:00 am, 1:00 pm and 3:00 pm at Courtyard Riverside Downtown / Marriott, 1510 University Avenue, Riverside, CA 92507; Tuesday, March 10, 2015, at 11:00 am, 1:00 pm and 3:00 pm at Ayres Suites Ontario at the Mills Mall, 4370 Mills Circle, Ontario, CA 91764; and Saturday, March 21, 2015, at 11:00 am, 1:00 pm and 3:00 pm at Embassy Suites Hotel, 900 E Birch Street, Brea, CA 92821. Please RSVP at (949) 679-3889.

The Irvine Stem Cell Treatment Center (Irvine and Westlake), along with sister affiliates, the Miami Stem Cell Treatment Center (Miami; Boca Raton; Orlando; The Villages, Florida) and the Manhattan Regenerative Medicine Medical Group (Manhattan, New York), abide by approved investigational protocols using adult adipose derived stem cells (ADSCs) which can be deployed to improve patients quality of life for a number of chronic, degenerative and inflammatory conditions and diseases. ADSCs are taken from the patients own adipose (fat) tissue (found within a cellular mixture called stromal vascular fraction (SVF)). ADSCs are exceptionally abundant in adipose tissue. The adipose tissue is obtained from the patient during a 15 minute mini-liposuction performed under local anesthesia in the doctors office. SVF is a protein-rich solution containing mononuclear cell lines (predominantly adult autologous mesenchymal stem cells), macrophage cells, endothelial cells, red blood cells, and important Growth Factors that facilitate the stem cell process and promote their activity.

ADSCs are the bodys natural healing cells – they are recruited by chemical signals emitted by damaged tissues to repair and regenerate the bodys injured cells. The Irvine Stem Cell Treatment Center only uses Adult Autologous Stem Cells from a persons own fat No embryonic stem cells are used; and No bone marrow stem cells are used. Current areas of study include: Emphysema, COPD, Asthma, Heart Failure, Heart Attack, Parkinsons Disease, Stroke, Traumatic Brain Injury, Lou Gehrigs Disease, Multiple Sclerosis, Lupus, Rheumatoid Arthritis, Crohns Disease, Muscular Dystrophy, Inflammatory Myopathies, and degenerative orthopedic joint conditions (Knee, Shoulder, Hip, Spine). For more information, or if someone thinks they may be a candidate for one of the adult stem cell protocols offered by the Irvine Stem Cell Treatment Center, they may contact Dr. Gionis directly at (949) 679-3889, or see a complete list of the Centers study areas at: http://www.IrvineStemCellsUSA.com.

About the Irvine Stem Cell Treatment Center: The Irvine Stem Cell Treatment Center, along with sister affiliates, the Miami Stem Cell Treatment Center and the Manhattan Regenerative Medicine Medical Group, is an affiliate of the California Stem Cell Treatment Center / Cell Surgical Network (CSN); we are located in Irvine and Westlake, California. We provide care for people suffering from diseases that may be alleviated by access to adult stem cell based regenerative treatment. We utilize a fat transfer surgical technology to isolate and implant the patients own stem cells from a small quantity of fat harvested by a mini-liposuction on the same day. The investigational protocols utilized by the Irvine Stem Cell Treatment Center have been reviewed and approved by an IRB (Institutional Review Board) which is registered with the U.S. Department of Health, Office of Human Research Protection (OHRP); and our studies are registered with Clinicaltrials.gov, a service of the U.S. National Institutes of Health (NIH). For more information, visit our websites: http://www.IrvineStemCellsUSA.com, http://www.MiamiStemCellsUSA.com, or http://www.NYStemCellsUSA.com.

Originally posted here:
The Irvine Stem Cell Treatment Center Announces Adult Stem Cell Public Seminars in Riverside, Ontario, and Brea …

Cell Cure Neurosciences Ltd. Provides Update on its Product Development and Partnering Activities

Stem Cell Treatment | Posted by admin
Feb 18 2015

ALAMEDA, Calif. & JERUSALEM–(BUSINESS WIRE)–BioTime, Inc. (NYSE MKT: BTX) and its subsidiary Cell Cure Neurosciences Ltd. (Cell Cure) today provided an update on Cell Cures product development and partnering activities.

On February 16, 2015, Cell Cure opened the clinical trial of OpRegen titled Phase I/IIa Dose Escalation Safety and Efficacy Study of Human Embryonic Stem Cell-Derived Retinal Pigment Epithelium Cells Transplanted Subretinally in Patients with Advanced Dry-Form Age-Related Macular Degeneration with Geographic Atrophy at Hadassah University Medical Center in Jerusalem, Israel. Patient enrollment is expected to begin shortly. OpRegen consists of animal product-free retinal pigment epithelial (RPE) cells with high purity and potency.

On October 31, 2014, the United States Food and Drug Administration (FDA) cleared Cell Cure’s Investigational New Drug (IND) application to initiate the clinical trial of OpRegen in patients with the severe form of age-related macular degeneration (AMD) with geographic atrophy (GA). While treatment options exist for the treatment of the wet form of AMD, it amounts to only about 10% of the disease prevalence. There is currently no FDA-approved therapy for the dry form occurring in approximately 90% of those afflicted with AMD. Cell Cure intends to transplant OpRegen as a single dose into the subretinal space of patients eyes in order to test the safety and efficacy of the product in this leading cause of blindness.

The Phase I/IIa clinical trial, will evaluate three different dose regimens of OpRegen. Following transplantation, the patients will be followed for 12 months at specified intervals, to evaluate the safety and tolerability of the product. Following the initial 12 month period, patients will continue to be monitored at longer intervals for an additional period of time. A secondary objective of the clinical trial will be to examine the ability of transplanted OpRegen to engraft, survive, and moderate disease progression in the patients. In addition to thorough characterization of visual function, a battery of ophthalmic imaging modalities will be used to quantify structural changes and rate of GA expansion.

Cell Cure also announced today that the option granted to Teva Pharmaceutical Industries Ltd. (Teva) under a Research and Exclusive Option Agreement of October 7, 2010 to license-in rights to its OpRegen product has expired without having been exercised by Teva. Cell Cure will therefore be continuing the clinical development of OpRegen on its own and pursuing discussions with other potential strategic partners, including those that have already indicated interest in participating in development and commercialization of the product.

Cell Cure also announced that US patent No. 8,956,866 relating to a proprietary method of manufacturing RPE cells (the active ingredient of OpRegen) is expected to issue on February 17, 2015. This patent combined with other patents and patent applications in the BioTime family of companies provides significant patent protection for this novel therapeutic modality for AMD.

The large markets currently associated with therapies for the wet form of AMD combined with the elegance of RPE replacement therapy for the larger unmet needs associated with the dry form, highlights why Cell Cure has prioritized the development of this product, said Dr. Charles Irving, CEO of Cell Cure. We look forward to initiation of the trials and providing updates in the coming months.

About Age-Related Macular Degeneration

Age-related macular degeneration (AMD) is one of the major diseases of aging and is the leading eye disease responsible for visual impairment of older persons in the US, Europe and Australia. AMD affects the macula, which is the part of the retina responsible for sharp, central vision that is important for facial recognition, reading and driving. There are two forms of AMD. The dry form (dry-AMD) advances slowly and painlessly but may progress to geographic atrophy (GA) in which RPE cells and photoreceptors degenerate and are lost. Once the atrophy involves the fovea (the center of the macula), patients lose their central vision and may develop legal blindness. There are about 1.6 million new cases of dry-AMD in the US annually, and as yet there is no effective treatment for this condition. About 10% of patients with dry-AMD develop wet (or neovascular) AMD, the second main form of this disease, which usually manifests acutely and can lead to severe visual loss in a matter of weeks. Wet-AMD can be treated with currently-marketed VEGF inhibitors. However, such products typically require frequent repeated injections in the eye, and patients often continue to suffer from continued progression of the underlying dry-AMD disease process. Current estimated annual sales of VEGF inhibitors for the treatment of the wet form of AMD are estimated to be in excess of $5 billion worldwide. The root cause of the larger problem of dry-AMD is believed to be the dysfunction of RPE cells. One of the most exciting therapeutic approaches to dry-AMD is the transplantation of healthy, young RPE cells to support and replace the patients old degenerating RPE cells, which may prevent progression of the atrophy as well as the development of wet-AMD. Pluripotent stem cells, such as hESCs, can provide an unlimited source for the derivation of such healthy RPE cells for transplantation.

About OpRegen

Go here to read the rest:
Cell Cure Neurosciences Ltd. Provides Update on its Product Development and Partnering Activities